Supernus Pharmaceuticals Inc - Company Profile
Powered by
All the data and insights you need on Supernus Pharmaceuticals Inc in one report.
- Save hours of research time and resources with
our up-to-date Supernus Pharmaceuticals Inc Strategy Report
- Understand Supernus Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Supernus Pharmaceuticals Inc (Supernus Pharmaceuticals) is a specialty pharmaceutical company that develops and commercializes products for the treatment of central nervous system (CNS) diseases. The company's neurology portfolio consists of Oxtellar XR (oxcarbazepine), an adjunct therapy for the treatment of partial seizures; Trokendi XR (topiramate), an initial monotherapy in patients with partial-onset of primary generalized tonic-clonic seizures associated with Lennox-Gastaut syndrome; Apokyn, and Xadago for Parkinson’s disease and Myobloc for cervical dystonia and sialorrhea in adults. Its major pipeline products include SPN-830, SPN-817, and SPN-820. The company's technology platforms include Microtrol (multi particulate delivery platform), Solutrol (matrix delivery platform) and EnSoTrol (osmotic delivery system). The company majority customers include pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals is headquartered in Rockville, Maryland, the US.
Supernus Pharmaceuticals Inc premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Trokendi XR: | Supernus |
Migraine | XADAGO |
Epilepsy | MYOBLOC |
XYZ | XYZ |
XYZ | XYZ |
XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2023 | Others | In November, the company announced that the U.S. Food and Drug Administration acknowledged the resubmission of the new drug application for its apomorphine infusion device for the continuous treatment of motor fluctuations in Parkinson’s disease (PD). |
2023 | Others | In October, the company resubmitted its New Drug Application for its apomorphine infusion device for the continuous treatment of motor fluctuations in Parkinson’s disease. |
2023 | Contracts/Agreements | In February, the company entered into an agreement with UBS Bank USA providing the Company an uncommitted demand secured line of credit of up to $150 million, which can be drawn at any time |
Competitor Comparison
Key Parameters | Supernus Pharmaceuticals Inc | Glenmark Pharmaceuticals Ltd | Vanda Pharmaceuticals Inc | Acorda Therapeutics Inc | Sage Therapeutics Inc |
---|---|---|---|---|---|
Headquarters | United States of America | India | United States of America | United States of America | United States of America |
City | Rockville | Mumbai | Washington | Pearl River | Cambridge |
State/Province | Maryland | Maharashtra | WashingtonD.C. | New York | Massachusetts |
No. of Employees | 652 | 15,556 | 203 | 102 | 487 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Charles W. Newhall, III | Chairman | Executive Board | 2016 | 78 |
Jack A. Khattar | Secretary; President; Chief Executive Officer; Director | Executive Board | 2005 | 61 |
Timothy C. Dec | Chief Financial Officer; Senior Vice President | Senior Management | 2021 | 65 |
Jonathan Rubin, MD | Chief Medical Officer; Senior Vice President - Research and Development | Senior Management | 2021 | 61 |
Padmanabh P. Bhatt, Ph.D. | Senior Vice President - Intellectual Property; Chief Scientific Officer | Senior Management | 2012 | 65 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward